Product Description
Metronidazole is one of the mainstay drugs for the treatment of anaerobic bacterial infections, protozoal infections, and microaerophilic bacterial infections. It is cytotoxic to facultative anaerobic microorganism. Metronidazole diffuses into the organism, inhibits protein synthesis by interacting with DNA and causing a loss of helical DNA structure and strand breakage. Therefore, it causes cell death in susceptible organisms. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK539728/)
Mechanisms of Action: Nucleic Acid Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Vaginosis, Bacterial | Diarrhea
Known Adverse Events: Headache | Pruritus | Candidiasis | Candidiasis, Vulvovaginal | Diarrhea
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Denmark, France, South Africa, Spain, United States
Active Clinical Trial Count: 12
Highest Development Phases
Phase 3: Hidradenitis Suppurativa|Vaginal Discharge|Vaginitis|Vaginosis, Bacterial
Phase 2: Adenoma|Colorectal Cancer|Diverticulitis
Phase 1: Atrial Fibrillation|Vaginal Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DIREBIOT | P2 |
Not yet recruiting |
Diverticulitis |
2025-12-31 |
|
| ABCESS2 | P3 |
Not yet recruiting |
Hidradenitis Suppurativa |
2025-12-15 |
|
| FRENCH24 ANIS | P3 |
Active, not recruiting |
Unknown |
2025-04-03 |
|
| VIBRANT | P1 |
Recruiting |
Vaginal Diseases|Vaginosis, Bacterial |
2024-07-01 |